First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status Meeting Abstract
| Authors: | Gettinger, S. N.; Shepherd, F. A.; Antonia, S. J.; Brahmer, J. R.; Chow, L. Q. M.; Juergens, R. A.; Borghaei, H.; Shen, Y.; Harbison, C.; Alaparthy, S.; Chen, A. C.; Rizvi, N. A. |
| Abstract Title: | First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status |
| Meeting Title: | 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 32 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2014 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2014-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358613204089 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2014.32.15_suppl.8024 |
| Notes: | Meeting Abstract: 8024 -- Source: Wos |
